Abdulkadyrov K M, Moiseev S I, Shcherbakova E G, Balashova V A, Glazanova T V, Rukavitsyn O A, Martynkevich I S, Gritsaev S V, Blinov M N
Ter Arkh. 1995;67(6):59-63.
The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.
对国产α2干扰素制剂利福隆在体内和体外消除慢性髓性白血病病理性造血克隆的有效性进行了研究。给予利福隆1至30个月后，7%的患者出现细胞遗传学缓解，21%的患者出现血液学缓解，36%的患者出现部分血液学缓解。利福隆适用于无脾肿大的慢性髓性白血病。在疾病进展期，利福隆无效。利福隆治疗作用的机制包括三个方面：对造血前体细胞的直接抗增殖作用、细胞免疫激活以及对干细胞微环境的作用。
